2. Signaling Pathways
  3. Anti-infection
    Metabolic Enzyme/Protease
  4. HIV Protease

HIV Protease

HIV Protease

Related Products

PDF 0.19 MB

HIV protease, a homodimeric aspartyl protease, is crucial for the viral life-cycle, cleaving proviral polyproteins, hence creating mature protein components that are required for the formation of an infectious virus. HIV protease cleaves newly synthesized polyproteins at the appropriate places to create the mature protein components of an infectious HIV virion. HIV protease is a critical drug target in designing anti-retroviral drugs to treat HIV/AIDS (acquired immune deficiency syndrome).

HIV-1 protease permits viral maturation by processing the Gag and Gag-Pro-Pol polyproteins. It recognizes and cleaves more than 12 different substrates leading to viral maturation. Similar to that of HIV-1, HIV-2 protease is also a homodimeric aspartyl enzyme that plays a vital role in the HIV life-cycle through processing of Gag and Gag-Pro-Pol precursor polyproteins leading to viral maturation.

HIV Protease Related Products (189):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P0018
    Pepstatin
    		Inhibitor 99.90%
    Pepstatin (Pepstatin A) is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin also inhibits HIV protease.
    Pepstatin
  • HY-90001
    Ritonavir
    		Inhibitor 99.96%
    Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM. Ritonavir (ABT 538) can penetrate the blood brain barrier (BBB).
    Ritonavir
  • HY-17007
    Saquinavir
    		Inhibitor 99.77%
    Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir
  • HY-15287
    Nelfinavir
    		Inhibitor 98.65%
    Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent.
    Nelfinavir
  • HY-14588
    Lopinavir
    		Inhibitor 99.71%
    Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM.
    Lopinavir
  • HY-104052
    MK-8718
    		Inhibitor
    MK-8718 is a potent and orally active HIV protease inhibitor containing a morpholine aspartate binding group. MK-8718 can be used for the research of infection.
    MK-8718
  • HY-180567
    PAC-Phe-Val
    		Inhibitor
    PAC-Phe-Val is a potent HIV-1 protease inhibitor with an IC50 value of 33.10 nM. PAC-Phe-Val forms stable and strong interactions with critical active site residues, contributing to its high inhibitory potency. PAC-Phe-Val can be used for HIV/AIDS research.
    PAC-Phe-Val
  • HY-179586
    HIV-1-IN-91
    		Inhibitor
    HIV-1-IN-91 (Compound BAN) is a HIV-1 protease inhibitor.
    HIV-1-IN-91
  • HY-17367
    Atazanavir
    		Inhibitor 99.23%
    Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.
    Atazanavir
  • HY-17040
    Darunavir
    		Inhibitor 99.91%
    Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity.
    Darunavir
  • HY-15287A
    Nelfinavir Mesylate
    		Inhibitor 99.04%
    Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir Mesylate (AG 1343 Mesylate) is a broad-spectrum, anticancer agent.
    Nelfinavir Mesylate
  • HY-B0689A
    Indinavir sulfate
    		Inhibitor 99.97%
    Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a SARS-CoV 3CLpro inhibitor.
    Indinavir sulfate
  • HY-17003
    Saquinavir mesylate
    		Inhibitor 99.40%
    Saquinavir (Ro 31-8959) mesylate is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir mesylate also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir mesylate
  • HY-15148
    Tipranavir
    		Inhibitor 98.0%
    Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM. Tipranavir inhibits SARS-CoV-2 3CLpro activity.
    Tipranavir
  • HY-P0018A
    Pepstatin Trifluoroacetate
    		Inhibitor 98.77%
    Pepstatin (Pepstatin A) Trifluoroacetate is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Trifluoroacetate also inhibits HIV protease.
    Pepstatin Trifluoroacetate
  • HY-17430
    Amprenavir
    		Inhibitor 99.55%
    Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.
    Amprenavir
  • HY-17367A
    Atazanavir sulfate
    		Inhibitor 99.68%
    Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor with blood-brain barrier permeability. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.
    Atazanavir sulfate
  • HY-78726
    Fosamprenavir
    		Inhibitor 98.17%
    Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection.
    Fosamprenavir
  • HY-P0018B
    Pepstatin Ammonium
    		Inhibitor 99.76%
    Pepstatin (Pepstatin A) Ammonium is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Ammonium also inhibits HIV protease.
    Pepstatin Ammonium
  • HY-137697D
    ddCTP trisodium solution (100 mM)
    		Inhibitor 98.03%
    ddCTP trilithium solution (100 mM) is a chain-terminating dideoxynucleotide. ddCTP trilithium can be incorporated into an extending primer strand lacking a 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. In primer extension inhibition assays, ddCTP trilithium enables discrimination of nearly identical RNAs via distinguishable extension products.
    ddCTP trisodium solution (100 mM)